Cargando…

A Novel Model Incorporating Tumor Stiffness, Blood Flow Characteristics, and Ki-67 Expression to Predict Responses After Neoadjuvant Chemotherapy in Breast Cancer

OBJECTIVE: To investigate the ability of tumor stiffness, tumor blood flow, and Ki-67 expression alone or in combination in predicting the pathological response to neoadjuvant chemotherapy (NACT) in breast cancer. PATIENTS AND METHODS: This prospective cohort study included 145 breast cancer patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jing, Gao, Song, Zheng, Qiaojin, Kang, Ye, Li, Jianyi, Zhang, Shuo, Shang, Cong, Tan, Xueying, Ren, Weidong, Ma, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753215/ https://www.ncbi.nlm.nih.gov/pubmed/33364197 http://dx.doi.org/10.3389/fonc.2020.603574

Ejemplares similares

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Kim, Kwan Il, et al.
Publicado: (2014)

Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
por: Wang, Yihua, et al.
Publicado: (2021)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

HIF-1α, TWIST-1 and ITGB-1, associated with Tumor Stiffness, as Novel Predictive Markers for the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Zhang, Jing, et al.
Publicado: (2020)

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
por: Fasching, Peter A, et al.
Publicado: (2011)

Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy
por: Tan, Shirong, et al.
Publicado: (2021)

Degree of Resection and Ki-67 Labeling Index for Recurring Meningiomas
por: Menger, Richard, et al.
Publicado: (2017)

Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms
por: Mao, Xia, et al.
Publicado: (2023)

Nomogram Based on CT Radiomics Features Combined With Clinical Factors to Predict Ki-67 Expression in Hepatocellular Carcinoma
por: Wu, Cuiyun, et al.
Publicado: (2022)

Prognostic and Clinicopathological Value of Ki-67 in Melanoma: A Meta-Analysis
por: Liu, Qixin, et al.
Publicado: (2021)

CT Radiomics Model for Predicting the Ki-67 Index of Lung Cancer： An Exploratory Study
por: Fu, Qing, et al.
Publicado: (2021)

Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
por: Ingolf, Juhasz-Böss, et al.
Publicado: (2014)

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
por: Ács, Balázs, et al.
Publicado: (2017)

A Nomogram for Preoperatively Predicting the Ki-67 Index of a Pituitary Tumor: A Retrospective Cohort Study
por: Cai, Xiangming, et al.
Publicado: (2021)

Ki-67 and Its Relation With Complete Pathological Response in Patients With Breast Cancer
por: Wajid, Sana, et al.
Publicado: (2021)

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
por: Hao, Junmei, et al.
Publicado: (2021)

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
por: Chen, Rui, et al.
Publicado: (2018)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

A nomogram incorporating Ki67 to predict survival of acral melanoma
por: Du, Yu, et al.
Publicado: (2023)

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
por: Burcombe, Russell, et al.
Publicado: (2006)

Relationship Between Ultrasound Features and Ki-67 Labeling Index of Soft Tissue Sarcoma
por: Wang, Pingping, et al.
Publicado: (2021)

Based on clinical Ki-67 expression and serum infiltrating lymphocytes related nomogram for predicting the diagnosis of glioma-grading
por: Zhang, Zhi, et al.
Publicado: (2022)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
por: Ding, Yuqin, et al.
Publicado: (2020)

CT Radiomics for the Preoperative Prediction of Ki67 Index in Gastrointestinal Stromal Tumors: A Multi-Center Study
por: Zhao, Yilei, et al.
Publicado: (2021)

Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer
por: Chen, Chunfa, et al.
Publicado: (2019)

Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer
por: LIN, QI, et al.
Publicado: (2013)

Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers
por: Srivastava, Pooja, et al.
Publicado: (2022)

The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy
por: Elmahs, Aya, et al.
Publicado: (2022)

Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
por: Silva, Leonardo Roberto da, et al.
Publicado: (2019)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis
por: Wu, Qiang, et al.
Publicado: (2019)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014
por: Moazed, Vahid, et al.
Publicado: (2018)

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
por: Tao, Miaomiao, et al.
Publicado: (2017)

Evaluation of the Therapeutic Effect of Adjuvant Transcatheter Arterial Chemoembolization Based on Ki67 After Hepatocellular Carcinoma Surgery
por: Zhao, Yu-Fei, et al.
Publicado: (2021)

Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis
por: Naheed, Salma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l4cm02u20r4456n9aa56daqb2k